C WORLDWIDE MEDICAL SMALL & MID CAP (1A) AS OF 31 JANUARY 2019
NET OF FEES IN EUR
STRATEGY
The investment objective of the C WorldWide Medical Small & Mid Cap fund is to achieve long-term capital growth by investing globally in a limited number of companies within healthcare. Investments are made in small and medium-sized companies in the pharmaceutical, biotechnology, medical technology, and healthcare sectors.
Our management team has a close collaboration with a scientific advisory board made up of leading scientists at the Karolinska Institute. This gives us unique insight into the forefront of medical research and valuable knowledge for example in evaluating the commercial potential of research projects.
Our investment decisions are based on thorough, fundamental research. This analysis is combined with dialogue with scientists as mentioned above and creates opportunities to put together a concentrated portfolio of 25-50 companies which we have detailed knowledge of, and which in our opinion constitute the most interesting investment opportunities in the long term.
INVESTMENT RETURNS
|
|
Portfolio |
|
Benchmark |
TOP 10 HOLDINGS
| Share in % | |
| Novocure | 5.7 % |
| Exact Sciences | 5.0 % |
| Oncopeptides | 4.9 % |
| Sarepta Therapeutics | 3.7 % |
| Portola Pharmaceuticals | 3.5 % |
| Horizon Pharma | 3.4 % |
| LHC Group | 3.3 % |
| Dexcom | 3.1 % |
| Collegium Pharmaceutical | 3.1 % |
| Insulet | 3.1 % |
RETURN & RISK
| 1 Y | 3 Y | 5 Y | 10 Y | Lifetime | P.A. | |
| Portfolio (%) | 8.5 | 43.8 | 75.8 | 306.3 | 1,787.3 | 15.4 |
| Benchmark (%) | 5.0 | 52.5 | 89.3 | 402.1 | 727.2 | 10.9 |
| Relative performance (%) | 3.5 | -8.8 | -13.6 | -95.7 | 1,060.1 | 4.6 |
| 3 Y | 5 Y | 10 Y | Lifetime | P.A. | ||
| Std. dev. portfolio (%) | 25.9 | 29.9 | 25.4 | 29.4 | 29.4 | |
| Std. dev. benchmark (%) | 22.2 | 25.1 | 22.0 | 27.2 | 27.2 | |
| Beta | 1.0 | 1.1 | 1.1 | 0.9 | 0.9 |
GEOGRAPHIC DIVERSIFICATION
SECTOR EXPOSURE
FACTS
| Fond: |
C WorldWide Medical Small & Mid Cap 1A |
| Security identifier (ISIN): | LU0091821107 |
| Launch date: | 3 August 1998 |
| Management fee: | 1.70% per annum |
| Dealing frequency: | Daily |
| Base currency: | EUR |
| Minimum investment: | EUR 1,000 |
| Benchmark: | Russell 2000® Healthcare |
| NAV as of 31 January 2019: | 377.45 |
| Fund AUM: | 113.9 million |
| Investment Manager: |
C WorldWide Asset Management, Stockholm |
| Portfolio Manager: |
Mikael Svensson, Angelica Fatouros, Ulf Arvidsson |
DISCLAIMER
The fact sheet is for information purposes only. The fact sheet does not constitute, and shall not be considered as, an offer or invitation to purchase or sell any fund. The information, calculations etc. shall not be considered investment advice or requests to engage in investment operations.
All reasonable precautions have been taken to ensure the correctness and accuracy of the fact sheet. However, the correctness and accuracy is not guaranteed and C WorldWide Asset Management Fondsmaeglerselskab A/S accepts no liability for any errors, spelling mistakes or omissions.
All figures are based on past performance. Past performance is not a reliable indicator of future performance. The currency is EUR. The return may increase or decrease as a result of currency fluctuations.
The figures are net of fees. Other fees, incurred by the investor, such as custody fees and transaction costs, are not included.
Russell Investment Group is the source and owner of the trademarks, service marks and copyrights related to the Russell Indexes. Russell® is a trademark of Russell Investment Group.